Attovia expands its IPO filing to 17M shares at an estimated $17, but retail access is still unverified
Attovia's latest SEC filing expands its proposed IPO to 17 million shares at an estimated $17, but no mainstream retail allocation is publicly verified; NASN TECH's Hong Kong offer has closed.
August 4, 2026 is a regular NYSE trading day. The date is not on the exchange's 2026 holiday or early-close list. 1
Today's spotlight: Attovia Therapeutics (ATTO)
Status: Attovia's latest SEC registration filing, submitted August 4, is still preliminary. It shows 17 million shares at an estimated $17 per share, with estimated net proceeds of $265.1 million. That implies about $289 million in gross proceeds before fees if the estimate holds. 2
That is a meaningful change from the July 29 filing, which showed 12.5 million shares at $15 to $17 and estimated net proceeds of $182.4 million. IPOScoop's public calendar still shows those older terms and an expected August 5 Nasdaq debut, so the final price and share count are not locked yet. 34
Business in one sentence: Attovia is a clinical-stage biotech developing multi-target biologic drugs for immune-mediated diseases through its ATTOBODY platform. Its lead program, ATTO-1310, is in Phase 1 for severe itching and related skin disease; ATTO-2306 and ATTO-1091 are earlier programs. 56
Why retail investors care: this is a large financing for a company that is still proving its first clinical programs. The latest filing reports about $115.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, before the IPO. Attovia expects to start a Phase 2 trial for ATTO-1310 by the first half of 2027. The offering would give the company more capital to reach that milestone, but it does not reduce the clinical risk. 2
Risk to monitor: Attovia has no products approved for commercial sale and has not generated product revenue. ATTO-1310 remains a Phase 1 program. A delayed or unsuccessful move into Phase 2 by the stated first-half-2027 target would be a clear reason to reassess the pipeline story. 2
Minimum buy-in and broker access: No public US retail allocation was verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. That leaves the minimum buy-in unconfirmed. An ATTO listing on a brokerage app would mean ordinary secondary-market trading, not proof that the IPO was available at the offer price.
Actionable now
No US IPO allocation met all four checks for this brief: public terms, a live deadline, a minimum buy-in, and a verified path through a mainstream retail broker. Calendar entries confirm upcoming deals, but they are not retail order notices. 47
| Ticker | Price range | Minimum buy-in | Deadline | Verified brokers | Status |
|---|---|---|---|---|---|
| None verified | - | - | No public US allocation window found | None publicly verified | Watch only |
ATTO, BRVE, and VOGX remain listing-watch names until a public allocation notice supplies the missing access and deadline details.
Market pulse
- The near-term calendar is biotech-heavy. Renaissance lists six current-week US deals: five biotech or therapeutics offerings and one bank IPO. The listed biotech sizes add up to about $972 million, led by Braveheart Bio at $300 million and Latigo at $272 million. That is a concentration of proposed supply, not proof of investor demand. 7
- Two SPAC units are marked priced today. IPOScoop lists ARC Group Securities Acquisition I at $10 per unit and BOA Acquisition Corp. II at $10 per unit, with estimated deal sizes of $105 million and $125 million. These are pricing or trading events, not verified public allocations for ordinary brokerage customers. 4
- The demand signal is missing. The accessible Attovia filing and public calendars do not provide an oversubscription multiple or a mainstream-broker allocation confirmation. The larger share count in the new filing shows a larger proposed financing; it does not tell you how strong the order book is. 2
HK desk
NASN TECH (2261) is closed for new applications in this edition. ET Net lists an offer range of HK$10.42 to HK$11.18 for a 100-share board lot, so the face-value minimum was HK$1,042 to HK$1,118 before fees. The application period ended at noon Hong Kong time on August 4, and the expected listing date is August 7. 8
NASN TECH develops intelligent-driving motion-control technology, with a focus on brake-by-wire systems. ET Net's August 4 new-listings memorandum confirms the August 7 debut. It does not identify a second active public offer in the same memo, so there is no additional verified Hong Kong action item here. 9
On the radar: August 5-12
The public profiles below give expected listing dates but do not separately disclose pricing dates. No pricing night is inferred.
| Deal | Pricing date | Expected listing | Terms | Why watch |
|---|---|---|---|---|
| Braveheart Bio (BRVE) | Not disclosed | Aug. 6 | 18.8M shares at $15-$17; est. $300M | Clinical-stage HCM drug candidate headed for planned global Phase 3 trials. 10 |
| Vogenx (VOGX) | Not disclosed | Aug. 6 | 6.25M shares at $11-$13; est. $75M | Phase 2B metabolic program for post-bariatric hypoglycemia; the company has never generated revenue. 11 |
| BlossomHill Therapeutics (BLSM) | Not disclosed | Aug. 7 | 7.81M shares at $15-$17; est. $125M | Phase 1/2 lung-cancer program with an FDA end-of-Phase 1 meeting planned for Q4 2026. 12 |
| Latigo Biotherapeutics (LTGO) | Not disclosed | Aug. 7 | 16M shares at $16-$18; est. $272M | Phase 3-ready, non-opioid oral therapies for acute and chronic pain. 13 |
| Londian Wason New Energy Tech (FOIL) | Not disclosed | Aug. 12 | 3.57M ADS at $20-$22; est. $75M | Makes copper foil used in lithium-ion batteries, giving the calendar a non-biotech industrial name. 14 |
Market information only, not investment advice. IPO terms, dates, and access can change before a final prospectus, pricing, or listing.
References
- 1NYSE holidays and trading hours
nyse.com
- 2Attovia latest S-1/A filing
sec.gov
- 3Attovia July 29 S-1/A filing
sec.gov
- 4IPOScoop IPO calendar
iposcoop.com
- 5Attovia IPO terms and business profile
renaissancecapital.com
- 6Attovia pipeline
attovia.com
- 7Renaissance Capital IPO calendar
renaissancecapital.com
- 8NASN TECH IPO details
etnet.com.hk
- 9ET Net August 4 new-listings memorandum
etnet.com.hk
- 10Braveheart Bio IPO profile
iposcoop.com
- 11Vogenx IPO profile
iposcoop.com
- 12BlossomHill IPO profile
iposcoop.com
- 13Latigo IPO profile
iposcoop.com
- 14Londian Wason IPO profile
iposcoop.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.